About: Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2006 (uk) article scientifique (publié 2006) (fr) im Jahr 2006 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2006 (ast) artikull shkencor i botuar më 01 janar 2006 (sq) scientific article published on 01 January 2006 (en)
publication date	wds:Q82181294-0F40B2C6-87C4-433F-AD34-858CAAE10F09
publication date	2006-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q82181294-314DCC2C-A6AA-4AE8-99AD-FC808895254D wds:Q82181294-5CC6CFAB-1F2B-4464-9DD6-9DC029D942B3 wds:Q82181294-8E089EEE-F69C-42F9-AB24-4DBF18A9EFBE wds:Q82181294-FC424840-8907-46F1-AACB-7A071AE7D79A
author name string	Leo M Schouls Sabine C de Greeff Lodewijk Spanjaard Arie van Derende
rdfs:label	Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (en) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (nl) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (sq)
skos:prefLabel	Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (en) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (nl) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (sq)
name	Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (en) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (nl) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (sq)
author	wds:Q82181294-8A7614DA-2268-419D-A24B-E29A428BA49D
author	Hester E. de Melker
title	wds:Q82181294-311EB4CF-2102-472C-B128-86761E250FEF
title	Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands (en)
page(s)	wds:Q82181294-9B3415D9-7929-4AC1-8763-DE95E187413C
page(s)	79-80
instance of	wds:Q82181294-829638D7-00D3-4120-8385-8ADD9F2182CF
instance of	scholarly article
main subject	wds:Q82181294-B1EAAD25-5464-4FA6-A6F1-CDB93DE28C3F
main subject	vaccine
PubMed ID	wds:Q82181294-C87B5F14-BEAD-4C4F-B84A-409792136354
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16395110
PubMed ID	16395110
published in	wds:Q82181294-324E5FDB-986E-47F1-8D5D-31EAD19AD44F
published in	Pediatric Infectious Disease Journal
issue	wds:Q82181294-442D2FF2-38C4-4A28-A104-26F5C1F99C78
volume	wds:Q82181294-AA22CAAA-0564-4C53-B62F-A080D2A28C9D
issue	1
volume	25
DOI	wds:Q82181294-7A52E00C-CE64-4815-A5D7-464CA875A089
DOI	http://dx.doi.org/10.1097/01.INF.0000195594.41449.C6
DOI	10.1097/01.INF.0000195594.41449.C6
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q82181294
is cites work of	Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults Meningococcal C conjugate vaccine: the experience in England and Wales Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults The changing and dynamic epidemiology of meningococcal disease Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Meningococcal carriage in the African meningitis belt Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG Protein carriers of conjugate vaccines: characteristics, development, and clinical trials Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil The promise of conjugate vaccines for Africa Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005 Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy Effectiveness of meningococcal serogroup C vaccine programmes Bacterial meningitis vaccination failure Developmental strategy fora new Group A meningococcal conjugate vaccine (MenAfriVacR). High tetanus antitoxin antibody concentrations in the Netherlands: a seroepidemiological study. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. History of meningococcal vaccines and their serological correlates of protection Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy Global practices of meningococcal vaccine use and impact on invasive disease Impact of vaccination on meningococcal epidemiology Association between season of vaccination and antibody levels against infectious diseases Meningococcal disease serogroup C. Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13. Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. Vaccination strategies for the prevention of meningococcal disease. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review Characteristics of meningococcal meningitis in children in France Vaccines for military use. Meningococcal conjugate vaccines: optimizing global impact Absence of Neisseria meningitidis serogroup C-specific antibodies during the first year of life in the Netherlands: an age group at risk? Meningococcal factor H binding protein fHbpd184 polymorphism influences clinical course of meningococcal meningitis Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software